Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 13:14:1084614.
doi: 10.3389/fphar.2023.1084614. eCollection 2023.

Adverse events of tumor necrosis factor alpha inhibitors for the treatment of ankylosing spondylitis: A meta-analysis of randomized, placebo-controlled trials

Haihuan Feng  1   2 , Ying Zhao  1 , Weihong Kuang  3 , Yanping Dai  1 , Xiaobo Cen  1 , Feng Qin  1   4
Affiliations

Adverse events of tumor necrosis factor alpha inhibitors for the treatment of ankylosing spondylitis: A meta-analysis of randomized, placebo-controlled trials

Haihuan Feng et al. Front Pharmacol. .

Abstract

Objective: Tumor necrosis factor alpha inhibitors (TNFi) have shown substantial efficacy in alleviating and treating ankylosing spondylitis (AS). However, the heightened interest is accompanied by concerns over adverse events. In this meta-analysis, we analyzed both serious and common adverse events in patients treated with tumor necrosis factor alpha inhibitors compared with those in the placebo group. Methods: We searched for clinical trials in PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Wanfang Data, and VIP Data. Studies were selected based on strict inclusion and exclusion criteria. Only randomized, placebo-controlled trials were included in the final analysis. RevMan 5.4 software was used for performing meta-analyses. Results: A total of 18 randomized controlled trials recruiting 3,564 patients with ankylosing spondylitis were included, with overall moderate to high methodological quality. Compared with the placebo group, the incidences showed no difference and were only slightly increased numerically for serious adverse events, serious infections, upper respiratory tract infection, and malignancies in patients treated with tumor necrosis factor alpha inhibitors. However, tumor necrosis factor alpha inhibitor treatment significantly increased the incidence of overall adverse events, nasopharyngitis, headache, and injection-site reactions in ankylosing spondylitis patients when compared with placebo. Conclusion: The available data indicated that ankylosing spondylitis patients who received tumor necrosis factor alpha inhibitors had no significantly increased risks of serious adverse events when compared with the placebo group. However, tumor necrosis factor alpha inhibitors significantly increased the incidence rate of common adverse events, including nasopharyngitis, headache, and injection-site reactions. Large-scale and long-term follow-up clinical trials are still necessary to further investigate the safety of tumor necrosis factor alpha inhibitors in ankylosing spondylitis treatment.

Keywords: adverse events; ankylosing spondylitis; infection; randomized controlled trial; tumor necrosis factor alpha inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Study selection process for the meta-analysis with specifications of reasons.
FIGURE 2
FIGURE 2
Pooled estimate of the incidence of overall adverse events between TNFi groups and placebo groups in patients with ankylosing spondylitis. The odds ratio >1.0 indicates that the incidence of serious adverse events is higher in the TNFi group than that in the placebo group. The subheading “Events” refers to the number of overall adverse events. “Total” refers to the total number of individuals. CI, confidence interval; df, degrees of freedom; M-H, Mantel–Haenszel method of calculation.
FIGURE 3
FIGURE 3
Pooled estimate of the incidence of nasopharyngitis between TNFi and placebo groups in patients with ankylosing spondylitis. The odds ratio >1.0 indicates that the incidence of nasopharyngitis is higher in the TNFi group than that in the placebo group. The subheading “Events” refers to the number of incidences of nasopharyngitis. “Total” refers to the total number of individuals. CI, confidence interval; df, degrees of freedom; M-H, Mantel–Haenszel method of calculation.
FIGURE 4
FIGURE 4
Pooled estimate of the incidence of headache between TNFi and placebo groups in patients with ankylosing spondylitis. The odds ratio >1.0 indicates that the incidence of headache is higher in the TNFi group than that in the placebo group. The subheading “Events” refers to the number of incidences of headache. “Total” refers to the total number of individuals. CI, confidence interval; df, degrees of freedom; M-H, Mantel–Haenszel method of calculation.
FIGURE 5
FIGURE 5
Pooled estimate of the incidence of injection-site reactions between TNFi and placebo groups in patients with ankylosing spondylitis. The odds ratio >1.0 indicates that the incidence of injection-site reactions is higher in the TNFi group than that in the placebo group. The subheading “Events” refers to the number of injection-site reactions. “Total” refers to the total number of individuals. CI, confidence interval; df, degrees of freedom; M-H, Mantel–Haenszel method of calculation.
See this image and copyright information in PMC

References

    1. Babuna Kobaner G., Polat Ekinci A., Yilmaz Z., Copur S. (2018). Psoriasiform skin eruption in a patient receiving certolizumab-pegol for ankylosing spondylitis: Report of a case and review of the literature. Dermatol. Ther. 31, e12693. 10.1111/dth.12693 - DOI - PubMed
    1. Bao C., Huang F., Khan M. A., Fei K., Wu Z., Han C., et al. (2014). Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatol. Oxf. 53, 1654–1663. 10.1093/rheumatology/keu132 - DOI - PubMed
    1. Bongartz T., Sutton A. J., Sweeting M. J., Buchan I., Matteson E. L., Montori V. (2006). Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275–2285. 10.1001/jama.295.19.2275 - DOI - PubMed
    1. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., et al. (2002). Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 359, 1187–1193. 10.1016/s0140-6736(02)08215-6 - DOI - PubMed
    1. Burmester G. R., Panaccione R., Gordon K. B., McIlraith M. J., Lacerda A. P. (2013). Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann. Rheum. Dis. 72, 517–524. 10.1136/annrheumdis-2011-201244 - DOI - PMC - PubMed

Publication types